CMC Contrast

CMC Contrast AB is developing CMC-001, a novel contrast agent for use in liver MRI in patients who are contraindicated or cannot be administered gadolinium-based contrast agents due to risk of serious side effects.

CMC Contrast AB is committed to develop CMC-001 to allow radiologists to perform contrast enhanced liver MRI for this patient population and thus become an important tool for clinicians to improve detection and localization of focal lesions of the liver. CMC-001 is the first contrast agent in the world to obtain Orphan Drug Designation by the FDA for use in liver MRI in patients for whom gadolinium-based contrast agents are contraindicated or cannot be administered.

Kategorier: Pharma

Gå till CMC Contrasts hemsida